Twist Bioscience (TWST) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $1.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.86%. A quarter ago, it was expected that this maker of synthetic DNA for the biotechnology industry would post a loss of $0.84 per share when it actually produced a loss of $0.79, delivering a surprise of 5.95%. Over ...

Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results – Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, increasing approximately 900 basis points over 34.4% in 3QFY23 – — Increased FY 2024 revenue guidance to approximately $310M to $311M; FY 2024 gross margin guidance at high end of the range at approximately 42.0% — — Company to host conference call today at 8:00 a.m. Eastern Time — SOUTH SAN FRANCISCO, C ...

Twist Bioscience (TWST) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of busi ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

Twist Bioscience Corporation (NASDAQ:TWST) Q2 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Steven Mah - Cowen Tom Peterson - Baird Operator Welcome to Twist Bioscience's Fiscal 2024 Second Quarter Financial Results Conference Call. At this time, all ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...

Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results – Record revenue of $75.3M in 2QFY24, an increase of 25% over $60.2M in 2QFY23 – – Orders increased to $93.2M in 2QFY24, growth of 45% over $64.2M in 2QFY23 – — Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% — — Company to host conference call today at 4:30 p.m. Eastern Time — SOUTH SAN FRANCISCO, Calif. -- (May 2, 2024) — Twist Bioscience C ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 in Boston, ...

Yuichiro Chino/Moment via Getty Images Twist Bioscience (NASDAQ:TWST) recently reported strong results in Q1 FY2024, particularly given how tepid the demand environment is. While some of this strength is a mirage created by lumpy NGS revenue, Twist's business continues to scale and progress towards cash flow breakeven. The stock may not look particularly cheap given its rise over the past 3 months, but it should be kept in mind that both the Biopharma and Data Storage businesses have significant potenti ...

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System. “ Element continues to expand its customer base, brin ...